2010; Guglieri and Bushby 2010; Rodino-Klapac et al. 2013). Such therapies are beneficial for quality of life and managing comorbidities, but do not address the primary cause of the disease nor alter disease progression. Recent advances have given rise to promising potential therapies for DMD and have shown that molecular strategies can restore dystrophin in DMD muscle (Malik et al. 2010; Cirak et al. 2011; Mendell et al. 2013), for review see (Wilton and Fletcher 2013). This evidence concerns the gene DMD and Duchenne muscular dystrophy.